Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Relmada Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 79 | 2 | 69 | −8 |
| Shares | 13.6M | 593.3K | 12.4M | −586.4K (−4.5%) |
| Value | $40.7M | $1.78M | $40.2M | +$1.34M (+3.5%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Relmada Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 567,880 | $1.84M | 0.00% |
| Shay Capital LLC | 175,547 | $568.8K | 0.17% |
| ExodusPoint Capital Management, LP | 68,000 | $220.0K | 0.00% |
| Rothschild Investment LLC | 20,000 | $64.8K | 0.00% |
| HighTower Advisors, LLC | 10,000 | $32.0K | 0.00% |
| Golden State Equity Partners | 200 | $648 | 0.00% |
| Larson Financial Group LLC | 100 | $324 | 0.00% |
Sold out (15)
Institutions that held Relmada Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Silverarc Capital Management, LLC | 99,379 | $298.1K |
| Guild Investment Management, Inc. | 73,596 | $220.8K |
| ADAR1 Capital Management, LLC | 50,601 | $151.8K |
| Jane Street Group, LLC | 37,476 | $112.4K |
| Squarepoint Ops LLC | 35,425 | $106.3K |
| Bank of Montreal | 19,900 | $62.7K |
| Belvedere Trading LLC | 13,029 | $39.1K |
| Cantor Fitzgerald, L. P. | 10,000 | $30.0K |
| Tower Research Capital LLC (TRC) | 2,754 | $8.26K |
| Rhumbline Advisers | 1,125 | $3.38K |
| GAMMA Investing LLC | 228 | $684 |
| Qube Research & Technologies Ltd | 56 | $168 |
| Russell Investments Group, Ltd. | 53 | $159 |
| Smartleaf Asset Management LLC | 35 | $104 |
| Innealta Capital, LLC | 5 | $15 |
Not filed for Q3 2024 yet (2)
Institutions that held Relmada Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 573,314 | $1.72M |
| Spotlight Asset Group, Inc. | 20,000 | $60.0K |